Roche Holding AG $RHHBY Shares Newly Bought by Associated Banc Corp

Key Points

• Associated Banc Corp initiated a position in Roche during Q3, buying 33,295 shares valued at approximately $1.74 million.
• Several other institutional investors also added Roche shares, including S&CO Inc., which increased its position by 163% in Q1.
• Analysts have a Moderate Buy consensus rating, with an average price target of $60; eight analysts rate the stock Buy and six rate it Hold.

Associated Banc Corp purchased a new position in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 33,295 shares of the company's stock, valued at approximately $1,740,000.

A number of other large investors have also recently bought and sold shares of the company. S&CO Inc. grew its position in Roche by 163.0% during the first quarter. S&CO Inc. now owns 140,551 shares of the company's stock valued at $6,880,000 after buying an additional 87,107 shares during the period. Opal Capital LLC acquired a new position in shares of Roche in the first quarter worth about $4,448,000. GAMMA Investing LLC boosted its stake in shares of Roche by 15.3% during the 3rd quarter. GAMMA Investing LLC now owns 33,458 shares of the company's stock worth $1,736,000 after acquiring an additional 4,443 shares in the last quarter. North Star Asset Management Inc. purchased a new stake in shares of Roche during the 2nd quarter worth about $1,351,000. Finally, Puzo Michael J acquired a new stake in shares of Roche during the 2nd quarter valued at about $1,229,000.

Roche Price Performance

Roche stock opened at $60.94 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.23 and a quick ratio of 0.95. Roche Holding AG has a fifty-two week low of $40.52 and a fifty-two week high of $61.49. The stock has a 50-day simple moving average of $55.75 and a 200-day simple moving average of $53.83.

Analysts Set New Price Targets

RHHBY has been the subject of several research analyst reports. Royal Bank Of Canada began coverage on Roche in a research note on Tuesday, September 8th. They set an "outperform" rating for the company. HSBC reissued a "hold" rating on shares of Roche in a report on Thursday, September 10th. Morgan Stanley upgraded shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price objective for the company in a research report on Friday, August 7th. Oddo Bhf raised Roche to an "outperform" rating in a research note on Tuesday, October 20th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a "hold" rating to a "buy" rating in a report on Friday, October 23rd. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Roche Profile

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company's pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.